The government and private players need to work together in the healthcare sector to increase the affordability of medical services as rising cost impacts access to patients, experts said
Private Healthcare in India Part III: Enforcing Clinical Establishment Act, capping drug costs can help regulate, reduce hospital bills
Clinical Establishment Act requires the Centre to set a range of rates for healthcare services. But neither the central nor any state govt has done so.
Private Healthcare in India Part I: Artificially-inflated cost of medicine, consumables make non-govt hospitals inaccessible to most
Inflated medical bills, artificially increased costs of medical supplies and consumables have hampered access to private healthcare in India.
India rejects US request on price caps on medical devices as Centre aims to boost affordability of treatment
Price controls form part of PM Modi’s agenda to improve India’s dilapidated public health system and boost affordability of treatment.
Non-scheduled drugs and diagnostic services constituted major components of charges billed to patients in four private hospitals with margins as high as 1,192 percent, drug pricing regulator NPPA said on Tuesday
NPPA sets deadline to lower prices of syringes and needles; manufacturers volunteer, set trade margin at 75%
Syringe and needle manufacturers set trade margins at maximum 75 percent in an attempt to self-regulate prices; NPPA sets deadline to 26 January
Gurugram child dies of dengue: NPPA says Fortis overcharged patient's family by margin as high as 1700%
Fortis hospital at Gurgaon charged as high as 1,700 percent margin on consumables and medicines used for the treatment of a dengue patient who subsequently died of the illness, the National Pharmaceutical Pricing Authority (NPPA) said
Drug price regulator caps prices of 51 essential formulations used for cancer, heart, skin treatment
NPPA fixes ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013
The National Pharmaceutical Pricing Authority (NPPA) on Wednesday fixed the price for primary knee replacement of titanium alloy at Rs 38,740 while the price for revision knee replacement of any material was pegged at Rs 62,770.
NPPA has capped the price of widely used Cromium Cobalt knee implants at Rs 54,720 from earlier Rs 1.58-Rs 2.5 lakh
National Pharmaceutical Pricing Authority (NPPA) said that the actual increase or decrease in prices after the rollout of new indirect tax regime is expected to be in be in the range of 2-3 per cent depending on states
The government has fixed GST rate of 12 percent on most of the essential drugs as against the current tax incidence of around 9 percent
Over the last few months, the National Pharmaceutical Pricing Authority (NPPA) has been in a tussle with manufacturers of cardiac stents.
Cost of cardiac stents cut by 75%: Dept of pharmaceuticals prohibits manufacturers from withdrawing products
After the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, reduced the price of cardiac stents by almost 75 percent, the government now has prohibited stent-makers from withdrawing their products from the market for the next six months.
Ceiling prices of 464 formulations have been fixed by the government after the announcement of NLEM, 2015 and revised Schedule-I
Medicines like paracetamol and antibiotics like cefadroxil and cefazolin have been brought under the price control ambit for the first time
Prices may come down of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and high blood pressure, with the government fixing their ceiling prices under the drug pricing control mechanism.
The report of the committee is yet to be submitted, State Minister of Chemicals and Fertilizers Hans Raj Gangaram Ahir informed Parliament.
The bulk drug formulations that have been added to the controlled list include those containing Paracetamol, Glucose, Amoxycilline, Diazepam,